| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| VRCAVerrica Pharmaceuticals Inc. | 121.68M | 7.61 | -0.51 | 47.66% | -84.38% | -15.47% |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 12M | 9.03M | 5.12M | 7.57M |
| Revenue Growth % | - | - | - | - | - | - | -0.25% | -0.43% | 0.48% |
| Cost of Goods Sold | 0 | 0 | 20.29K | 257.2K | 229K | 472K | 725K | 746K | 2.74M |
| COGS % of Revenue | - | - | - | - | - | 0.04% | 0.08% | 0.15% | 0.36% |
| Gross Profit | 0 | 0 | -20.29K | -257.2K | -229K | 11.53M | 8.31M | 4.38M | 4.83M |
| Gross Margin % | - | - | - | - | - | 0.96% | 0.92% | 0.85% | 0.64% |
| Gross Profit Growth % | - | - | - | -11.67% | 0.11% | 51.34% | -0.28% | -0.47% | 0.1% |
| Operating Expenses | 1.91M | 4.46M | 21.88M | 29.82M | 39.95M | 42.44M | 29.6M | 70.14M | 70.75M |
| OpEx % of Revenue | - | - | - | - | - | 3.54% | 3.28% | 13.69% | 9.35% |
| Selling, General & Admin | 204K | 727K | 9.05M | 14.39M | 24.51M | 26.98M | 17.41M | 47.3M | 58.82M |
| SG&A % of Revenue | - | - | - | - | - | 2.25% | 1.93% | 9.23% | 7.77% |
| Research & Development | 1.71M | 3.73M | 12.83M | 15.44M | 15.67M | 15.93M | 12.2M | 20.3M | 11.84M |
| R&D % of Revenue | - | - | - | - | - | 1.33% | 1.35% | 3.96% | 1.56% |
| Other Operating Expenses | 0 | 0 | -1K | 0 | -229K | -472K | 0 | 2.54M | 83K |
| Operating Income | -1.91M | -4.46M | -21.88M | -30.08M | -40.18M | -30.91M | -21.3M | -65.76M | -65.92M |
| Operating Margin % | - | - | - | - | - | -2.58% | -2.36% | -12.83% | -8.71% |
| Operating Income Growth % | - | -1.33% | -3.91% | -0.37% | -0.34% | 0.23% | 0.31% | -2.09% | -0% |
| EBITDA | 0 | 0 | -21.86M | -29.82M | -39.95M | -30.44M | -20.58M | -64.92M | -64.65M |
| EBITDA Margin % | - | - | - | - | - | -2.54% | -2.28% | -12.67% | -8.54% |
| EBITDA Growth % | - | - | - | -0.36% | -0.34% | 0.24% | 0.32% | -2.15% | 0% |
| D&A (Non-Cash Add-back) | 1.91M | 4.46M | 20.29K | 257.2K | 229K | 472K | 718K | 836K | 1.27M |
| EBIT | -1.91M | -4.46M | -20.65M | -28.21M | -39.66M | -30.79M | -22.32M | -63.03M | -67.17M |
| Net Interest Income | 0 | 0 | 0 | 1.88M | -2.51M | -4.17M | -1.7M | -1.22M | -8M |
| Interest Income | 0 | 0 | 1.23M | 1.88M | 521K | 123K | 476K | 2.74M | 1.42M |
| Interest Expense | 0 | 2K | 0 | 0 | 3.03M | 4.29M | 2.17M | 3.96M | 9.41M |
| Other Income/Expense | 0 | -2K | 1.23M | 1.87M | -2.51M | -4.17M | -3.19M | -1.24M | -10.66M |
| Pretax Income | -1.91M | -4.46M | -20.65M | -28.21M | -42.69M | -35.08M | -24.49M | -67M | -76.58M |
| Pretax Margin % | - | - | - | - | - | -2.92% | -2.71% | -13.07% | -10.12% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1.07% | 1% | 1% | 1% | 1% |
| Net Income | -1.91M | -4.46M | -20.65M | -28.21M | -45.5M | -35.08M | -24.49M | -67M | -76.58M |
| Net Margin % | - | - | - | - | - | -2.92% | -2.71% | -13.07% | -10.12% |
| Net Income Growth % | - | -1.33% | -3.63% | -0.37% | -0.61% | 0.23% | 0.3% | -1.74% | -0.14% |
| Net Income (Continuing) | -1.91M | -4.46M | -20.65M | -28.21M | -42.69M | -35.08M | -24.49M | -67M | -76.58M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.74 | -3.80 | -14.08 | -11.33 | -17.08 | -12.97 | -7.17 | -14.78 | -14.78 |
| EPS Growth % | - | -4.1% | -2.71% | 0.2% | -0.51% | 0.24% | 0.45% | -1.06% | 0% |
| EPS (Basic) | -0.74 | -3.80 | -14.08 | -11.33 | -17.08 | -12.97 | -7.17 | -14.78 | -14.78 |
| Diluted Shares Outstanding | 2.57M | 2.57M | 1.47M | 2.49M | 2.5M | 2.7M | 3.42M | 4.53M | 5.18M |
| Basic Shares Outstanding | 2.57M | 2.57M | 1.47M | 2.49M | 2.5M | 2.7M | 3.42M | 4.53M | 5.18M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 544K | 9.08M | 91.15M | 64.98M | 67.65M | 74.33M | 39.12M | 77.53M | 51.18M |
| Cash & Short-Term Investments | 527K | 8.66M | 89.81M | 62.02M | 65.47M | 70.35M | 34.27M | 69.55M | 46.33M |
| Cash Only | 527K | 8.66M | 10.27M | 9.24M | 10.69M | 15.75M | 34.27M | 69.55M | 46.33M |
| Short-Term Investments | 0 | 0 | 79.54M | 52.78M | 54.78M | 54.6M | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 487K | 4.42M | 77K |
| Days Sales Outstanding | - | - | - | - | - | - | 19.68 | 314.57 | 3.71 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.02M | 2.46M |
| Days Inventory Outstanding | - | - | - | - | - | - | - | 500.04 | 328.1 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 4.36M | 2.54M | 2.31M |
| Total Non-Current Assets | 0 | 0 | 754K | 3.44M | 6.5M | 5.8M | 5.61M | 4.07M | 2.96M |
| Property, Plant & Equipment | 0 | 0 | 255K | 2.2M | 4.94M | 5.5M | 5.33M | 3.62M | 2.58M |
| Fixed Asset Turnover | - | - | - | - | - | 2.18x | 1.69x | 1.42x | 2.93x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 499K | 1.24M | 1.57M | 295K | 276K | 452K | 376K |
| Total Assets | 544K | 9.08M | 91.91M | 68.42M | 74.15M | 80.13M | 44.72M | 81.6M | 54.13M |
| Asset Turnover | - | - | - | - | - | 0.15x | 0.20x | 0.06x | 0.14x |
| Asset Growth % | - | 15.7% | 9.12% | -0.26% | 0.08% | 0.08% | -0.44% | 0.82% | -0.34% |
| Total Current Liabilities | 419K | 616K | 2.48M | 3.35M | 39.48M | 46.05M | 3.46M | 17.02M | 29.01M |
| Accounts Payable | 103K | 167K | 960K | 1.19M | 348K | 845K | 507K | 2.46M | 1.9M |
| Days Payables Outstanding | - | - | 17.27K | 1.68K | 554.67 | 653.44 | 255.25 | 1.21K | 252.57 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 35.31M | 41.69M | 0 | 0 | 12.94M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 500K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 49K | 1.26M | 1.2M | 1.34M | 1.67M | 1.4M | 9.04M | 11.59M |
| Current Ratio | 1.30x | 14.75x | 36.80x | 19.39x | 1.71x | 1.61x | 11.31x | 4.55x | 1.76x |
| Quick Ratio | 1.30x | 14.75x | 36.80x | 19.39x | 1.71x | 1.61x | 11.31x | 4.49x | 1.68x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | -390.97 | 79.25 |
| Total Non-Current Liabilities | 2.79M | 15.51M | 0 | 58K | 1.69M | 1.47M | 1.23M | 44.81M | 34.98M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42.87M | 30.98M |
| Capital Lease Obligations | 0 | 0 | 0 | 58K | 1.69M | 1.47M | 1.23M | 1.94M | 1.35M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.79M | 15.51M | 0 | 0 | 0 | 0 | 0 | 0 | 2.65M |
| Total Liabilities | 3.21M | 16.12M | 2.48M | 3.41M | 41.17M | 47.52M | 4.69M | 61.83M | 63.99M |
| Total Debt | 0 | 0 | 0 | 188K | 37.21M | 43.41M | 1.53M | 45.51M | 45.94M |
| Net Debt | -527K | -8.66M | -10.27M | -9.05M | 26.52M | 27.66M | -32.75M | -24.04M | -390K |
| Debt / Equity | - | - | - | 0.00x | 1.13x | 1.33x | 0.04x | 2.30x | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -2228.50x | - | - | -13.25x | -7.20x | -9.80x | -16.60x | -7.00x |
| Total Equity | -2.66M | -7.04M | 89.43M | 65.02M | 32.99M | 32.6M | 40.03M | 19.76M | -9.86M |
| Equity Growth % | - | -1.64% | 13.7% | -0.27% | -0.49% | -0.01% | 0.23% | -0.51% | -1.5% |
| Book Value per Share | -1.04 | -2.74 | 60.99 | 26.11 | 13.20 | 12.06 | 11.72 | 4.36 | -1.90 |
| Total Shareholders' Equity | -2.66M | -7.04M | 89.43M | 65.02M | 32.99M | 32.6M | 40.03M | 19.76M | -9.86M |
| Common Stock | 0 | 0 | 3K | 3K | 3K | 3K | 4K | 4K | 9K |
| Retained Earnings | -2.68M | -12.44M | -33.08M | -61.19M | -103.89M | -138.97M | -163.45M | -230.45M | -307.03M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -17K | 20K | 1K | -29K | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.61M | -4.58M | -17.87M | -27.41M | -30.21M | -27.58M | -18.65M | -38.58M | -60.93M |
| Operating CF Margin % | - | - | - | - | - | -2.3% | -2.06% | -7.53% | -8.05% |
| Operating CF Growth % | - | -1.84% | -2.9% | -0.53% | -0.1% | 0.09% | 0.32% | -1.07% | -0.58% |
| Net Income | -1.91M | -4.46M | -20.65M | -28.21M | -42.69M | -35.08M | -24.49M | -67M | -76.58M |
| Depreciation & Amortization | 0 | 0 | 20K | 257.2K | 229K | 472K | 718K | 836K | 1.27M |
| Stock-Based Compensation | 9K | 82K | 2.25M | 0 | 0 | 6.05M | 4.99M | 14.38M | 7.16M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 66K | 0 | 0 | 0 |
| Other Non-Cash Items | -62K | 18K | -435K | 2.27M | 10.62M | 1.44M | 1.93M | 3.35M | 5.19M |
| Working Capital Changes | 293K | -206K | 938K | -1.73M | 1.64M | -535K | -1.8M | 9.86M | 2.03M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | -487K | -3.93M | 4.34M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 487K | 0 | 0 |
| Change in Payables | 71K | 64K | 793K | 225K | -838K | 497K | -338K | 2.2M | -568K |
| Cash from Investing | 0 | 0 | -79.89M | 25.95M | -3.58M | -998K | 54.04M | -362K | -19K |
| Capital Expenditures | 0 | 0 | -774K | -682K | -1.47M | -883K | -302K | -362K | -27K |
| CapEx % of Revenue | - | - | - | - | - | 0.07% | 0.03% | 0.07% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -499K | -1.22M | -221K | -201K | -180K | 0 | 8K |
| Cash from Financing | 483K | 12.72M | 99.38M | 423K | 35.23M | 33.65M | -16.87M | 74.21M | 37.73M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - |
| Other Financing | -17K | -281K | 0 | 0 | 410K | 558K | -17K | -169K | 155K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -1.61M | -4.58M | -18.65M | -28.09M | -31.68M | -28.46M | -18.95M | -38.94M | -60.95M |
| FCF Margin % | - | - | - | - | - | -2.37% | -2.1% | -7.6% | -8.06% |
| FCF Growth % | - | -1.84% | -3.07% | -0.51% | -0.13% | 0.1% | 0.33% | -1.05% | -0.57% |
| FCF per Share | -0.63 | -1.78 | -12.72 | -11.28 | -12.67 | -10.53 | -5.55 | -8.59 | -11.77 |
| FCF Conversion (FCF/Net Income) | 0.84x | 1.03x | 0.87x | 0.97x | 0.66x | 0.79x | 0.76x | 0.58x | 0.80x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -50.12% | -36.53% | -92.85% | -106.97% | -67.42% | -224.08% | -1546.58% |
| Return on Invested Capital (ROIC) | - | - | -51.72% | -33.39% | -52.2% | -38.71% | -47.29% | -3274.85% | - |
| Gross Margin | - | - | - | - | - | 96.07% | 91.97% | 85.44% | 63.79% |
| Net Margin | - | - | - | - | - | -292.33% | -271.11% | -1307.47% | -1012.15% |
| Debt / Equity | - | - | - | 0.00x | 1.13x | 1.33x | 0.04x | 2.30x | - |
| Interest Coverage | - | -2228.50x | - | - | -13.25x | -7.20x | -9.80x | -16.60x | -7.00x |
| FCF Conversion | 0.84x | 1.03x | 0.87x | 0.97x | 0.66x | 0.79x | 0.76x | 0.58x | 0.80x |
| Revenue Growth | - | - | - | - | - | - | -24.73% | -43.27% | 47.66% |
| 2023 | 2024 | |
|---|---|---|
| Product | 4.66M | 6.57M |
| Product Growth | - | 41.13% |
| Collaboration | 466K | 992K |
| Collaboration Growth | - | 112.88% |
Verrica Pharmaceuticals Inc. (VRCA) reported $30.8M in revenue for fiscal year 2024.
Verrica Pharmaceuticals Inc. (VRCA) grew revenue by 47.7% over the past year. This is strong growth.
Verrica Pharmaceuticals Inc. (VRCA) reported a net loss of $26.0M for fiscal year 2024.
Verrica Pharmaceuticals Inc. (VRCA) has a return on equity (ROE) of -1546.6%. Negative ROE indicates the company is unprofitable.
Verrica Pharmaceuticals Inc. (VRCA) had negative free cash flow of $29.1M in fiscal year 2024, likely due to heavy capital investments.